Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Molecular Partners AG’s MOLN share price has surged by 9.28%, which has investors questioning if this is right time to sell.

European shares were subdued in early trading on Wednesday, as cautious investors held out from making big bets while ...

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Connor Clark & Lunn Investment Management Ltd. lowered its position in Novartis AG (NYSE:NVS – Free Report) by 95.6% in the 4th quarter, according to the company in its most recent Form 13F filing ...

Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...